These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19552609)

  • 1. Malignant pleural mesothelioma: current treatments and emerging drugs.
    Belli C; Fennell D; Giovannini M; Gaudino G; Mutti L
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):423-37. PubMed ID: 19552609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
    Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodality therapy in mesothelioma: role of chemotherapy.
    Vogelzang NJ
    Thorac Surg Clin; 2004 Nov; 14(4):531-42. PubMed ID: 15559060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the systemic therapy of malignant pleural mesothelioma.
    Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J
    Nat Clin Pract Oncol; 2008 Mar; 5(3):136-47. PubMed ID: 18227828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
    Budde LS; Hanna NH
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M; Gatzemeier U
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
    Tomek S; Manegold C
    Lung Cancer; 2004 Aug; 45 Suppl 1():S103-19. PubMed ID: 15261443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.
    Pasello G; Ceresoli GL; Favaretto A
    Cancer Treat Rev; 2013 Feb; 39(1):10-7. PubMed ID: 22459200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
    Hanauske AR
    Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of malignant pleural mesothelioma].
    Yusa T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):520-6. PubMed ID: 17431335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
    Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A
    Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.
    Greillier L; Marco S; Barlesi F
    Anticancer Drugs; 2011 Mar; 22(3):199-205. PubMed ID: 21263312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review on clinical trials of targeted treatments in malignant mesothelioma.
    Jakobsen JN; Sørensen JB
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):1-15. PubMed ID: 21553148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for malignant mesothelioma.
    Taub RN; Antman KH
    Semin Thorac Cardiovasc Surg; 1997 Oct; 9(4):361-6. PubMed ID: 9352953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current trends in the management of malignant pleural mesothelioma.
    Tsiouris A; Gourgoulianis KI; Walesby RK
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):831-3. PubMed ID: 16761925
    [No Abstract]   [Full Text] [Related]  

  • 20. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
    Orbaugh KK
    Clin J Oncol Nurs; 2004 Jun; 8(3):242-7. PubMed ID: 15208818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.